Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology
Silvia Sookoian, Carlos J. Pirola, Luca Valenti, et al.
Hepatology (2020) Vol. 72, Iss. 1, pp. 330-346
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1223
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Herbert Tilg, Timon E. Adolph, Michael Dudek, et al.
Nature Metabolism (2021) Vol. 3, Iss. 12, pp. 1596-1607
Closed Access | Times Cited: 307
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade
Herbert Tilg, Timon E. Adolph, Alexander R. Moschen
Hepatology (2020) Vol. 73, Iss. 2, pp. 833-842
Open Access | Times Cited: 298
Geographical similarity and differences in the burden and genetic predisposition of NAFLD
Terry Cheuk‐Fung Yip, Eduardo Vilar‐Gómez, Salvatore Petta, et al.
Hepatology (2022) Vol. 77, Iss. 4, pp. 1404-1427
Closed Access | Times Cited: 80
From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease
Mary E. Rinella, Silvia Sookoian
Journal of Lipid Research (2023) Vol. 65, Iss. 1, pp. 100485-100485
Open Access | Times Cited: 77
NASH drug treatment development: challenges and lessons
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 49
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 35
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
Allison Soto, Colby Spongberg, Alessandro Martinino, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 397-397
Open Access | Times Cited: 22
Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects
Søren Møller, Nina Kimer, Jens D. Hove, et al.
European Journal of Preventive Cardiology (2025)
Closed Access | Times Cited: 2
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
Anne Fougerat, Alexandra Montagner, Nicolas Loiseau, et al.
Cells (2020) Vol. 9, Iss. 7, pp. 1638-1638
Open Access | Times Cited: 114
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis
K. Teo, Kushala Abeysekera, Leon A. Adams, et al.
Journal of Hepatology (2020) Vol. 74, Iss. 1, pp. 20-30
Open Access | Times Cited: 108
Liver‐Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer
Elizabeth P. Newberry, Zoe Hall, Yan Xie, et al.
Hepatology (2021) Vol. 74, Iss. 3, pp. 1203-1219
Open Access | Times Cited: 90
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Marco Arrese, Juan Pablo Arab, Francisco Barrera, et al.
Seminars in Liver Disease (2021) Vol. 41, Iss. 04, pp. 421-434
Open Access | Times Cited: 79
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management
Amedeo Lonardo, Juan Pablo Arab, Marco Arrese
Advances in Therapy (2021) Vol. 38, Iss. 5, pp. 2130-2158
Open Access | Times Cited: 67
Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD
Sílvia Vilarinho, Veeral Ajmera, Melanie Zheng, et al.
Hepatology (2021) Vol. 74, Iss. 4, pp. 2241-2250
Open Access | Times Cited: 66
Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD/MAFLD)
Christina‐Maria Flessa, Ioannis Kyrou, Narjes Nasiri‐Ansari, et al.
Journal of Cellular Biochemistry (2022) Vol. 123, Iss. 10, pp. 1585-1606
Closed Access | Times Cited: 52
Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2
Boushra Bathish, Holly Robertson, John Dillon, et al.
Free Radical Biology and Medicine (2022) Vol. 188, pp. 221-261
Open Access | Times Cited: 51
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Ibon Martínez-Arránz, Chiara Bruzzone, Mazen Noureddin, et al.
Hepatology (2022) Vol. 76, Iss. 4, pp. 1121-1134
Open Access | Times Cited: 49
The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes
Minxuan Xu, Jun Tan, Wei Dong, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 40
METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression
Yue-fan Wang, Wenli Zhang, Zhi-xuan Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 15
Genetics of MASLD: The State of Art Update.
Silvia Sookoian, Yaron Rotman, Luca Valenti
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 11, pp. 2177-2187.e3
Closed Access | Times Cited: 15
Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
Seyedeh Kosar Mahmoudi, Shadi Tarzemani, Taha Aghajanzadeh, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 14
Organoid-guided precision hepatology for metabolic liver disease
Sho Osonoi, Takanori Takebe
Journal of Hepatology (2024) Vol. 80, Iss. 5, pp. 805-821
Closed Access | Times Cited: 11
The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions
Carlos J. Pirola, Tomas Fernández Gianotti, Silvia Sookoian
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Effects of the triglyceride-glucose index on non-alcoholic fatty liver disease: causal evidence from longitudinal cohort studies
Tengrui Cao, Xuetong Ni, Aheyeerke Halengbieke, et al.
Archives of Gerontology and Geriatrics (2025) Vol. 133, pp. 105813-105813
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top